GlycoMimetics EPS - Earnings per Share 2012-2025 | CBIO
GlycoMimetics eps - earnings per share from 2012 to 2025. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| GlycoMimetics Annual EPS |
| 2024 |
$-0.59 |
| 2023 |
$-0.58 |
| 2022 |
$-0.89 |
| 2021 |
$-1.23 |
| 2020 |
$-1.12 |
| 2019 |
$-1.34 |
| 2018 |
$-1.18 |
| 2017 |
$-1.13 |
| 2016 |
$-1.50 |
| 2015 |
$-0.67 |
| 2014 |
$-0.60 |
| 2013 |
$-8.87 |
| 2012 |
$0.33 |
| 2011 |
$-6.58 |
| GlycoMimetics Quarterly EPS |
| 2025-03-31 |
$-0.04 |
| 2024-12-31 |
$-0.11 |
| 2024-09-30 |
$-0.15 |
| 2024-06-30 |
$-0.16 |
| 2024-03-31 |
$-0.17 |
| 2023-12-31 |
$-0.14 |
| 2023-09-30 |
$-0.14 |
| 2023-06-30 |
$-0.13 |
| 2023-03-31 |
$-0.17 |
| 2022-12-31 |
$-0.20 |
| 2022-09-30 |
$-0.16 |
| 2022-06-30 |
$-0.25 |
| 2022-03-31 |
$-0.28 |
| 2021-12-31 |
$-0.33 |
| 2021-09-30 |
$-0.34 |
| 2021-06-30 |
$-0.28 |
| 2021-03-31 |
$-0.28 |
| 2020-12-31 |
$-0.33 |
| 2020-09-30 |
$-0.29 |
| 2020-06-30 |
$-0.32 |
| 2020-03-31 |
$-0.18 |
| 2019-12-31 |
$-0.33 |
| 2019-09-30 |
$-0.31 |
| 2019-06-30 |
$-0.37 |
| 2019-03-31 |
$-0.33 |
| 2018-12-31 |
$-0.32 |
| 2018-09-30 |
$-0.27 |
| 2018-06-30 |
$-0.26 |
| 2018-03-31 |
$-0.33 |
| 2017-12-31 |
$-0.25 |
| 2017-09-30 |
$-0.24 |
| 2017-06-30 |
$-0.30 |
| 2017-03-31 |
$-0.34 |
| 2016-12-31 |
$-0.35 |
| 2016-09-30 |
$-0.34 |
| 2016-06-30 |
$-0.41 |
| 2016-03-31 |
$-0.40 |
| 2015-12-31 |
$-0.43 |
| 2015-09-30 |
$-0.38 |
| 2015-06-30 |
$0.51 |
| 2015-03-31 |
$-0.37 |
| 2014-12-31 |
$-0.34 |
| 2014-09-30 |
$-0.35 |
| 2014-06-30 |
$0.39 |
| 2014-03-31 |
$-0.30 |
| 2013-12-31 |
$-2.21 |
| 2013-09-30 |
$-3.00 |
| 2013-06-30 |
$-3.70 |
| 2013-03-31 |
$0.04 |
| 2012-12-31 |
$0.00 |
| 2012-09-30 |
$0.00 |
| 2011-12-31 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.009B |
$0.000B |
|
GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
| OncoCyte (IMDX) |
United States |
$0.090B |
0.00 |
